Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
BOSTON and ATLANTA, Aug. 26, 2022 -- (Healthcare Sales & Marketing Network) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parki... Biopharmaceuticals, Oncology, FDA Inhibikase Therapeutics, imatinib , Chronic Myelogenous Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2022 Category: Pharmaceuticals Source Type: news
'Rogue' Online Pharmacies Are Dispensing Cancer Drugs
(MedPage Today) -- Dozens of illegitimate online pharmacies are selling imatinib, an oral chemotherapy drug for chronic myeloid leukemia (CML), putting patients at risk for toxicities and treatment failures, researchers found.
Of 44 online pharmacies... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 29, 2022 Category: American Health Source Type: news
Division of Hematologic Malignancies 1 (DHM1)
regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologic Licensing Applications (BLAs) for Acute Leukemia and Myelodysplasia and Chronic Myeloid Leukemia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 10, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Alembic gets USFDA nod for cancer treatment drug
Dasatinib Tablet is indicated for the treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 10, 2022 Category: Pharmaceuticals Source Type: news
Belong.Life rolls out online community for patients with chronic myeloid leukemia
Patients can use the service to access support groups, navigation tools and a clinical trial-matching program. (Source: mobihealthnews)
Source: mobihealthnews - January 13, 2022 Category: Information Technology Source Type: news
How Long Can You Live With Chronic Myeloid Leukemia?
Title: How Long Can You Live With Chronic Myeloid Leukemia?Category: Diseases and ConditionsCreated: 1/7/2022 12:00:00 AMLast Editorial Review: 1/7/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - January 7, 2022 Category: Cancer & Oncology Source Type: news
Retrospective study finds that cancer drug also lowers blood glucose
ROCHESTER, Minnesota — Dasatinib, a drug that often is used to treat certain types of leukemia, may have antidiabetic effects comparable to medications used to treat diabetes, and with more research may become a novel therapy for diabetic patients, according to new research published in Mayo Clinic Proceedings. Dasati nib is a tyrosine kinase inhibitor used to treat tumors and malignant tissue, as well as chronic myelogenous leukemia. Researchers at Mayo Clinic and the University of… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - November 9, 2021 Category: Research Source Type: news
FDA Approves Asciminib, Drug With Novel Action in CML FDA Approves Asciminib, Drug With Novel Action in CML
This first-in-class STAMP inhibitor is approved for use in patients with chronic myeloid leukemia who have developed resistance to tyrosine kinase inhibitors.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Scemblix (asciminib) for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML)
Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor (TKI) treatments1
In the pivotal... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 29, 2021 Category: Drugs & Pharmacology Source Type: news
FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia
On October 29, 2021, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 29, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
On the Horizon: Asciminib, a New Drug for Treating R/R CML On the Horizon: Asciminib, a New Drug for Treating R/R CML
A first-in-class STAMP inhibitor, asciminib, shows better efficacy than bosutinib in patients with relapsed/refractory chronic myeloid leukemia in the chronic phase.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Tyrosine Kinase Inhibitor Discontinuation Can Improve CML Outcomes Tyrosine Kinase Inhibitor Discontinuation Can Improve CML Outcomes
In patients with chronic myeloid leukemia (CML), discontinuing tyrosine kinase inhibitor (TKI) therapy is safe and associated with better patient-reported outcomes, a nonrandomized trial reveals.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Are We Close to Predicting Treatment-Free Remission in CML? Are We Close to Predicting Treatment-Free Remission in CML?
Chronic myeloid leukemia expert Dr Richard Stone discusses the promise and clinical feasibility of two recently proposed predictive scores.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Renal Function Decline With TKI Use in Chronic Myeloid Leukaemia Renal Function Decline With TKI Use in Chronic Myeloid Leukaemia
Tyrosine kinase inhibitors are associated with renal function decline in patients with chronic myeloid leukaemia according to results of a 10-year follow up.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
The CNIO reprograms CRISPR system in mice to eliminate tumor cells without affecting healthy cells
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) CNIO researchers destroyed Ewing's sarcoma and chronic myeloid leukaemia tumor cells by using CRISPR to cut out the fusion genes that cause them. For the first time, fusion genes have been selectively and efficiently removed using CRISPR. These genes are attracting a great deal of interest from the research community because they are unique to the tumor cell and are therefore excellent targets for the development of future drugs that only attack the tumor and are harmless for healthy cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2020 Category: Cancer & Oncology Source Type: news
